Safety and Tolerability of a Candidate Bioconjugate Vaccine Against Shigella Flexneri 2a When Administered to Adult Volunteers.

Trial Profile

Safety and Tolerability of a Candidate Bioconjugate Vaccine Against Shigella Flexneri 2a When Administered to Adult Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Shigella flexneri 2A vaccine (Primary)
  • Indications Bacillary dysentery
  • Focus Adverse reactions
  • Sponsors GlycoVaxyn
  • Most Recent Events

    • 21 Dec 2015 Status changed from active, no longer recruiting to completed as reported by Clinicaltrials.gov record.
    • 30 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by Clinicaltrials.gov record.
    • 16 Mar 2015 Status changed from planning to recruiting as reported by Clinicaltrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top